{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:42:21Z","timestamp":1791805341186,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R03 AG074030-01"],"award-info":[{"award-number":["R03 AG074030-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5-K12-CA120780-13"],"award-info":[{"award-number":["5-K12-CA120780-13"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011531","name":"University of Alabama","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jtct.2022.03.006","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T12:09:04Z","timestamp":1647000544000},"page":"294-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":143,"title":["Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8481-3046","authenticated-orcid":false,"given":"Shakira J.","family":"Grant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa A.","family":"Grimshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Silberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Murdaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1479-7626","authenticated-orcid":false,"given":"Tanya M.","family":"Wildes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Rosko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smith","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.03.006_bib0001","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.03.006_bib0002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.03.006_bib0003","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.03.006_bib0004","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.03.006_bib0005","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.03.006_bib0006","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.03.006_bib0007","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1097\/HS9.0000000000000191","article-title":"In the eye of the storm: immune-mediated toxicities associated with CAR T cell therapy","volume":"3","author":"Garcia Borrega","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtct.2022.03.006_bib0008","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.006_bib0009","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2022.03.006_bib0010","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2022.03.006_bib0011","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/jnen\/nly064","article-title":"Neuropathology of a case with fatal CAR T-cell-associated cerebral edema","volume":"77","author":"Torre","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.jtct.2022.03.006_bib0012","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.jtct.2022.03.006_bib0013","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.006_bib0014","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.006_bib0015","first-page":"372:n71.","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jtct.2022.03.006_bib0016","first-page":"368:I6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jtct.2022.03.006_bib0017","series-title":"JBI Manual for Evidence Synthesis","article-title":"Chapter 7: Systematic reviews of etiology and risk","author":"Moola","year":"2020"},{"key":"10.1016\/j.jtct.2022.03.006_bib0018","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.006_bib0019","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1177\/0962280219889080","article-title":"Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis","volume":"29","author":"McGrath","year":"2020","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jtct.2022.03.006_bib0020","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/CJI.0000000000000241","article-title":"Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy","volume":"41","author":"Shalabi","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.jtct.2022.03.006_bib0021","doi-asserted-by":"crossref","first-page":"18997","DOI":"10.1038\/s41598-020-76055-9","article-title":"Description of neurotoxicity in a series of patients treated with CAR T-cell therapy","volume":"10","author":"Belin","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtct.2022.03.006_bib0022","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.03.006_bib0023","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/WNP.0000000000000669","article-title":"EEG correlates of delirium in children and young adults with CD19-directed CAR T cell treatment-related neurotoxicity","volume":"38","author":"Gust","year":"2021","journal-title":"J Clin Neurophysiol"},{"key":"10.1016\/j.jtct.2022.03.006_bib0024","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jtct.2022.03.006_bib0025","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/neuonc\/noab077","article-title":"Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study","volume":"23","author":"Maillet","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jtct.2022.03.006_bib0026","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.03.006_bib0027","doi-asserted-by":"crossref","first-page":"E427","DOI":"10.1002\/ajh.26330","article-title":"Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel","volume":"96","author":"Wudhikarn","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.03.006_bib0028","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.25315","article-title":"Neurotoxicity after CTL019 in a pediatric and young adult cohort","volume":"84","author":"Gofshteyn","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jtct.2022.03.006_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2020-000054","article-title":"Language dysfunction-associated EEG findings in patients with CAR-T-related neurotoxicity","volume":"2","author":"Sokolov","year":"2020","journal-title":"BMJ Neurol Open"},{"key":"10.1016\/j.jtct.2022.03.006_bib0030","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.03.006_bib0031","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","article-title":"Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes","volume":"23","author":"Holtzman","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jtct.2022.03.006_bib0032","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1182\/bloodadvances.2019001305","article-title":"Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.03.006_bib0033","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2217\/imt-2020-0161","article-title":"Neurological adverse events following CAR T-cell therapy: a real-world analysis","volume":"12","author":"Gajra","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jtct.2022.03.006_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.634445","article-title":"Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-cell therapy: can we optimize early diagnosis?","volume":"11","author":"Brown","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2022.03.006_bib0035","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2217\/imt-2021-0084","article-title":"Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study","volume":"13","author":"Yuen","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jtct.2022.03.006_bib0036","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/neuonc\/noab174","article-title":"EEG findings in CAR T-cell-associated neurotoxicity: clinical and radiological correlations","volume":"24","author":"Beuchat","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jtct.2022.03.006_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.03.005","article-title":"Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and\/or siltuximab following CAR T cell therapy","volume":"434","author":"Chen","year":"2016","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jtct.2022.03.006_bib0038","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann Neurol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.03.006_bib0039","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.03.006_bib0040","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/blood-2021-146927","article-title":"A phase II trial of anakinra for the prevention of CAR-T cell mediated neurotoxicity","volume":"138","author":"Frigault","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.03.006_bib0041","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/blood-2021-147454","article-title":"Safety and efficacy of two anakinra dose regimens for refractory CRS or ICANS after CAR T-cell therapy","volume":"138","author":"Gazeau","year":"2021","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2022.03.006_bib0042","doi-asserted-by":"crossref","first-page":"8028","DOI":"10.1200\/JCO.2021.39.15_suppl.8028","article-title":"Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2","volume":"39","author":"Einsele","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2022.03.006_bib0043","doi-asserted-by":"crossref","first-page":"7532","DOI":"10.1200\/JCO.2021.39.15_suppl.7532","article-title":"CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL","volume":"39","author":"Gauthier","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.03.006_bib0044","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood-2021-149674","article-title":"Pre-infusion neurofilament light chain (NfL) levels predict the development of immune effector cell-associated neurotoxicity syndrome (ICANS)\u2014a multicenter retrospective study","volume":"138","author":"Butt","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.03.006_bib0045","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood-2021-152875","article-title":"EASIX predicts severe cytokine release syndrome (CRS) and immune effector cell-associated neuro-toxicity syndrome (ICANS) in patients receiving CD19-directed chimeric antigen receptor T (CAR-T) cell therapy","volume":"138","author":"Korell","year":"2021","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722001531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722001531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:04:45Z","timestamp":1763003085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722001531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2666636722001531"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.03.006","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}